BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, Hüttemann M, Taub JW, Ge Y. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther 2020;5:288. [PMID: 33335095 DOI: 10.1038/s41392-020-00361-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Trac QT, Zhou T, Pawitan Y, Vu TN. Discovery of druggable cancer-specific pathways with application in acute myeloid leukemia. Gigascience 2022;11:giac091. [PMID: 36173247 DOI: 10.1093/gigascience/giac091] [Reference Citation Analysis]
2 Yang C, Gu Y, Song C, Ge Z. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia. IJMS 2022;23:11393. [DOI: 10.3390/ijms231911393] [Reference Citation Analysis]
3 Peklar B, Perdih F, Makuc D, Plavec J, Cluzeau J, Kitanovski Z, Časar Z. Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue. Pharmaceutics 2022;14:1641. [PMID: 36015269 DOI: 10.3390/pharmaceutics14081641] [Reference Citation Analysis]
4 Liu Y, Li H, Zhao Y, Li D, Zhang Q, Fu J, Fan S. Targeting FHL1 impairs cell proliferation and differentiation of acute myeloid leukemia cells. Biochem Cell Biol 2022. [PMID: 35916339 DOI: 10.1139/bcb-2021-0507] [Reference Citation Analysis]
5 Bouligny IM, Maher KR, Grant S. Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100996] [Reference Citation Analysis]
6 Ren T, Wang J, Tang W, Chen D, Wang S, Zhang X, Yang D. ARID1A has prognostic value in acute myeloid leukemia and promotes cell proliferation via TGF-β1/SMAD3 signaling. Clin Exp Med 2022. [PMID: 35867200 DOI: 10.1007/s10238-022-00863-8] [Reference Citation Analysis]
7 Zhang K, Gao L, Wang J, Chu X, Zhang Z, Zhang Y, Fang F, Tao Y, Li X, Tian Y, Li Z, Sang X, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Pan J, Hu S. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. Pathol Oncol Res 2022;28:1610447. [DOI: 10.3389/pore.2022.1610447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhang Y, Li N, Chang Z, Wang H, Pei H, Zhang D, Zhang Q, Huang J, Guo Y, Zhao Y, Pan Y, Chen C, Chen Y. The Metabolic Signature of AML Cells Treated With Homoharringtonine. Front Oncol 2022;12:931527. [DOI: 10.3389/fonc.2022.931527] [Reference Citation Analysis]
9 Liu H, Zhang X, Zhao Z, Zhu H, Li D, Yang Y, Zhao W, Zhang F, Wang Y, Zhu L, Ding Z, Li X. CNST is Characteristic of Leukemia Stem Cells and is Associated With Poor Prognosis in AML. Front Pharmacol 2022;13:888243. [PMID: 35662693 DOI: 10.3389/fphar.2022.888243] [Reference Citation Analysis]
10 Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, Belloucif Y, Laiguillon MC, Meduri E, Vaganay C, Alexe G, Berrou J, Benaksas C, Forget A, Braun T, Gardin C, Raffoux E, Clappier E, Adès L, de Thé H, Fenaille F, Huntly BJ, Stegmaier K, Dombret H, Fenouille N, Lobry C, Puissant A, Itzykson R. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia 2022. [PMID: 35474100 DOI: 10.1038/s41375-022-01573-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Narayan N, Huntly BJP. Targeting AML at the intersection of epigenetics and signaling. Sci Signal 2022;15:eabo0059. [PMID: 35439022 DOI: 10.1126/scisignal.abo0059] [Reference Citation Analysis]
12 Yu H, Wu S, Liu S, Li X, Gai Y, Lin H, Wang Y, Edwards H, Ge Y, Wang G. Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. J Cell Mol Med 2022. [PMID: 35355406 DOI: 10.1111/jcmm.17274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Saad AA. Targeting cancer-associated glycans as a therapeutic strategy in leukemia. All Life 2022;15:378-433. [DOI: 10.1080/26895293.2022.2049901] [Reference Citation Analysis]
14 Harada T, Heshmati Y, Kalfon J, Perez MW, Xavier Ferrucio J, Ewers J, Hubbell Engler B, Kossenkov A, Ellegast JM, Yi JS, Bowker A, Zhu Q, Eagle K, Liu T, Kai Y, Dempster JM, Kugener G, Wickramasinghe J, Herbert ZT, Li CH, Vrabič Koren J, Weinstock DM, Paralkar VR, Nabet B, Lin CY, Dharia NV, Stegmaier K, Orkin SH, Pimkin M. A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes Dev 2022;36:368-89. [PMID: 35301220 DOI: 10.1101/gad.349284.121] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Yen S, Chen L, Huang H, Huangfu W, Chen Y, Eight Lin T, Lien S, Tseng H, Sung T, Hsieh J, Huang W, Pan S, Hsu K. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Unten Y, Murai M, Koshitaka T, Kitao K, Shirai O, Masuya T, Miyoshi H. Comprehensive understanding of multiple actions of anticancer drug tamoxifen in isolated mitochondria. Biochim Biophys Acta Bioenerg 2022;1863:148520. [PMID: 34896079 DOI: 10.1016/j.bbabio.2021.148520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Li L, Han C, Yu X, Shen J, Cao Y, Abdulhay E. Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis. Journal of Healthcare Engineering 2022;2022:1-7. [DOI: 10.1155/2022/2842066] [Reference Citation Analysis]
18 Walker OL, Dahn ML, Power Coombs MR, Marcato P. The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting. Front Oncol 2022;11:791696. [DOI: 10.3389/fonc.2021.791696] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Panuzzo C, Jovanovski A, Ali MS, Cilloni D, Pergolizzi B. Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling. JCM 2022;11:483. [DOI: 10.3390/jcm11030483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zeng YJ, Wu M, Zhang H, Wu XP, Zhou L, Wan N, Wu ZH. Effects of Qinghuang Powder on Acute Myeloid Leukemia Based on Network Pharmacology, Molecular Docking, and In Vitro Experiments. Evid Based Complement Alternat Med 2021;2021:6195174. [PMID: 34992668 DOI: 10.1155/2021/6195174] [Reference Citation Analysis]
21 Song YC, Kuo CC, Liu CT, Wu TC, Kuo YT, Yen HR. Combined Effects of Tanshinone IIA and an Autophagy Inhibitor on the Apoptosis of Leukemia Cells via p53, Apoptosis-Related Proteins and Oxidative Stress Pathways. Integr Cancer Ther 2022;21:15347354221117776. [PMID: 35996358 DOI: 10.1177/15347354221117776] [Reference Citation Analysis]
22 Seshacharyulu P, Halder S, Nimmakayala R, Rachagani S, Chaudhary S, Atri P, Chirravuri-Venkata R, Ouellette MM, Carmicheal J, Gautam SK, Vengoji R, Wang S, Li S, Smith L, Talmon GA, Klute K, Ly Q, Reames BN, Grem JL, Berim L, Padussis JC, Kaur S, Kumar S, Ponnusamy MP, Jain M, Lin C, Batra SK. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. EBioMedicine 2021;75:103772. [PMID: 34971971 DOI: 10.1016/j.ebiom.2021.103772] [Reference Citation Analysis]
23 Ganesan S, Mathews V, Vyas N. Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough? Int J Cancer 2021. [PMID: 34921734 DOI: 10.1002/ijc.33908] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
24 Baroud M, Lepeltier E, El-Makhour Y, Lautram N, Bejaud J, Thepot S, Duval O. Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes. Pharmaceuticals (Basel) 2021;14:1317. [PMID: 34959720 DOI: 10.3390/ph14121317] [Reference Citation Analysis]
25 Díaz M, Pibuel M, Paglilla N, Poodts D, Álvarez E, Papademetrio DL, Hajos SE, Lompardía SL. 4-Methylumbelliferone induces antitumor effects independently of hyaluronan synthesis inhibition in human acute leukemia cell lines. Life Sci 2021;287:120065. [PMID: 34678263 DOI: 10.1016/j.lfs.2021.120065] [Reference Citation Analysis]
26 Wu L, Chatla S, Lin Q, Chowdhury FA, Geldenhuys W, Du W. Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia. Nat Commun 2021;12:6936. [PMID: 34836965 DOI: 10.1038/s41467-021-27300-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Nguyen T, Pepper JW, Nguyen C, Fan Y, Hu Y, Chen Q, Yan C, Meerzaman D. Molecular Characterization of the Highest Risk Adult Patients With Acute Myeloid Leukemia (AML) Through Multi-Omics Clustering. Front Genet 2021;12:777094. [PMID: 34777485 DOI: 10.3389/fgene.2021.777094] [Reference Citation Analysis]
28 Cheng H, Ding J, Tang G, Huang A, Gao L, Yang J, Chen L. Human mesenchymal stem cells derived exosomes inhibit the growth of acute myeloid leukemia cells via regulating miR-23b-5p/TRIM14 pathway. Mol Med 2021;27:128. [PMID: 34656078 DOI: 10.1186/s10020-021-00393-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ 2021;375:n2026. [PMID: 34615640 DOI: 10.1136/bmj.n2026] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
30 Cairns LV, Lappin KM, Mutch A, Ali A, Matchett KB, Mills KI. Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia. Int J Mol Sci 2021;22:10163. [PMID: 34576326 DOI: 10.3390/ijms221810163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Fu X, He Y, Li M, Huang Z, Najafi M. Targeting of the tumor microenvironment by curcumin. Biofactors 2021. [PMID: 34375483 DOI: 10.1002/biof.1776] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
32 Yang L, Feng Y, Wang S, Jiang S, Tao L, Li J, Wang X. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia. Int Immunopharmacol 2021;99:107965. [PMID: 34273636 DOI: 10.1016/j.intimp.2021.107965] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Kumar S, Nagpal R, Kumar A, Ashraf MU, Bae YS. Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia. Biomedicines 2021;9:690. [PMID: 34207299 DOI: 10.3390/biomedicines9060690] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
34 Wu H, Zhang L, Zhu Z, Ding C, Chen S, Liu R, Fan H, Chen Y, Li H. Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy. Drug Deliv 2021;28:1166-78. [PMID: 34121564 DOI: 10.1080/10717544.2021.1934191] [Reference Citation Analysis]
35 Forsythe A, Sandman K. What Does the Economic Burden of Acute Myeloid Leukemia Treatment Look Like for the Next Decade? An Analysis of Key Findings, Challenges and Recommendations. J Blood Med 2021;12:245-55. [PMID: 33981169 DOI: 10.2147/JBM.S279736] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Qu M, Duan Y, Zhao M, Wang Z, Zhao M, Zhao Y, Wang H, Ke Y, Liu Y, Liu HM, Wei L, Hu Z. Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways. Front Oncol 2021;11:659720. [PMID: 33842376 DOI: 10.3389/fonc.2021.659720] [Cited by in F6Publishing: 5] [Reference Citation Analysis]